ADC Therapeutics S.A. logo

ADC Therapeutics S.A.

ADCT | NYSE
Chart Builder DCF Calculator
$1.12
+$0.07 (+6.67%)
At close: Sep 21, 2026, 4:00 PM ET
$1.07
-$0.05 (-4.63%)
After-hours: Sep 21, 2026, 6:09 PM ET

Market Data

Market Cap
$133.55M
Enterprise Value
$340.45M
Beta
1.85
Average Volume
1.78M
Shares Outstanding (Diluted)
155.02M
Shares Change YoY
36.29%
Institutional Ownership
54.18%
Exchange
NYSE
ISIN
CH0499880968

Price Performance

Price Change 1M
13.1%
Price Change 3M
-2.6%
Price Change 6M
-71.8%
Price Change YTD
-68.2%
Price Change 1Y
-67.8%
Price Change 3Y
55.6%
Price Change 5Y
-96.0%
1M CAGR (ann.)
-7.1%
1Y CAGR (ann.)
-67.7%
5Y CAGR (ann.)
-47.7%
All-Time CAGR
-40.9%

Valuation

PE Ratio
-1.70
Forward PE
N/A
PEG Ratio
-0.02
Forward PEG
0.15
PS Ratio
1.81
Forward PS
1.50
PB Ratio
-0.62
P/FCF Ratio
-1.39
P/Adj. FCF Ratio
-1.21
P/OCF Ratio
-1.70
EV/Sales
4.32
EV/EBIT
-3.87
EV/EBITDA
-3.89
EV/FCF
-3.33
Earnings Yield
-58.9%
FCF Yield
-71.8%
Adj. FCF Yield
-82.4%

Financial Health

Net Debt
$198M
Total Debt
$417.11M
Cash & Short-Term Investments
$219.11M
Total Assets
$279.38M
Current Ratio
3.03
Quick Ratio
2.97
Debt / Equity Ratio
-1.83
Debt / EBITDA
-4.77
Debt / FCF
-4.08
OCF / Debt
-0.25
Interest Coverage
-1.90
Altman Z-Score
-8.29
Piotroski F-Score
2

Margins & Profitability

Gross Profit Margin
88.8%
Operating Profit Margin
-125.8%
EBITDA Margin
-111.1%
Net Profit Margin
-123.0%
FCF Margin
-129.9%
Adj. FCF Margin
-149.1%
SBC / Revenue
19.2%
SBC Impact (per share)
-14.8%

Returns

Return on Assets
-34.7%
Return on Equity
44.6%
Return on Invested Capital
-49.5%
Return on Capital Employed
-51.3%
Return on Tangible Assets
-34.7%

Historical Growth (CAGR)

Revenue CAGR 3Y
-24.7%
Revenue CAGR 5Y
83.8%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
59.3%
EPS CAGR 5Y
22.4%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
18.1%
FCF CAGR 5Y
14.1%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Hold
Analyst Count
12
EPS Growth Next 3Y
38.4%
Revenue Growth Next 3Y
41.7%
Earnings Date
Nov 9, 2026
EPS Estimate (next Q)
-$0.21
EPS Growth Est (next Q)
-30.0%
Revenue Est (next Q)
$18.44M
Revenue Growth Est (next Q)
12.2%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$3.50
Price Target Upside
212.5%

Cash Flow

Operating Cash Flow
$-102.27M
Free Cash Flow
$-102.31M
Adj. Free Cash Flow
$-117.43M
FCF Per Share
-$0.66
OCF Per Share
-$0.66
OCF/S Ratio
-129.8%

Income Statement

Revenue
$78.77M
Gross Profit
$69.9M
Operating Income
$-99.11M
EBITDA
$-87.48M
Net Income
$-96.91M
EPS (Diluted)
-$0.66
Revenue / Employee
$412.39K
Profit / Employee
$-507.37K
Employees
191

© 2026 bestshares.com. All rights reserved.